

Montelukast Granules Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

SECTION 1. IDENTIFICATION

Product name : Montelukast Granules Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000

Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Montelukast	151767-02-1	>= 0,1 -< 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Sweep up or vacuum up spillage and collect in suitable container for disposal.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Montelukast	151767-02-1	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : No data available
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available
- Flammability (solid, gas) : May form explosive dust-air mixture during processing,

SAFETY DATA SHEET



Montelukast Granules Formulation



Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Montelukast Granules Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 5.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

Components:

Montelukast:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Montelukast:

Species : Rabbit
Result : Severe irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Montelukast:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

Product:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Components:**Montelukast:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Product:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Dose : 200 mg/kg body weight

Montelukast Granules Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

Result : negative
Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Dose : 100 mg/kg body weight
Result : negative

Components:**Montelukast:**

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Product:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL Parent: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL Parent: 200 mg/kg body weight
Symptoms: Reduced fertility

Components:**Montelukast:**

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 800 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, female
Application Route: Oral
Fertility: LOAEL: 200 mg/kg body weight
Symptoms: Reduced fertility

Test Type: Fertility

Montelukast Granules Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

Species: Rat, female
 Application Route: Oral
 Fertility: NOAEL: 100 mg/kg body weight
 Symptoms: Reduced fertility

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Montelukast:

Species : Monkey, male and female
 NOAEL : 150 - 300 mg/kg
 Application Route : Oral
 Exposure time : 53 Weeks
 Remarks : No significant adverse effects were reported

Species : Rat
 NOAEL : 50 mg/kg
 Application Route : Oral
 Exposure time : 53 Weeks
 Remarks : No significant adverse effects were reported

Species : Mouse
 NOAEL : 50 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Product:

Skin contact : Remarks: May irritate skin.
 Eye contact : Symptoms: Severe irritation
 Ingestion : Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever

Components:

Montelukast:

Skin contact : Remarks: May irritate skin.
 Eye contact : Symptoms: Severe irritation
 Ingestion : Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever

Montelukast Granules Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Montelukast:**

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0,0778 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 0,0675 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,073 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.
- NOEC (Cyprinodon variegatus (sheepshead minnow)): 0,0816 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,23 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Persistence and degradability**Components:****Montelukast:**

SAFETY DATA SHEET



Montelukast Granules Formulation



Version 3.1 Revision Date: 26.09.2023 SDS Number: 22978-00023 Date of last issue: 20.03.2023
Date of first issue: 17.10.2014

Biodegradability : Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21,7 h)

Bioaccumulative potential

Components:

Montelukast:

Partition coefficient: n-octanol/water : log Pow: > 4,3

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

SAFETY DATA SHEET



Montelukast Granules Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

Control of precursors and essential chemicals for the preparation of drugs : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 26.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-

SAFETY DATA SHEET



Montelukast Granules Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	22978-00023	Date of first issue: 17.10.2014

recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8